PURE Bioscience, Inc. PURE

Company Overview

PURE Bioscience, Inc. is a U.S.-based life sciences and antimicrobial technology company focused on developing and commercializing silver dihydrogen citrate-based antimicrobial products for food safety, sanitation, and infection control applications. The company operates primarily within the food safety, agriculture, and surface disinfection industries, with an emphasis on antimicrobial solutions designed to reduce pathogens and improve hygiene standards in commercial environments. PURE Bioscience has historically centered its business around proprietary silver-based chemistry technologies and related intellectual property.

The company’s principal revenue drivers have included licensing arrangements, product sales, and commercialization activities tied to its antimicrobial platform technology. PURE Bioscience has targeted food processors, foodservice operators, agriculture-related users, and institutional sanitation markets. Its strategic positioning has historically relied on patented silver dihydrogen citrate formulations intended to provide broad-spectrum antimicrobial efficacy while meeting regulatory standards for food-contact and hard-surface applications. Founded in 1992 and headquartered in California, the company evolved from a technology development enterprise into a commercialization-focused business centered on antimicrobial products and licensing opportunities.

Business Operations

PURE Bioscience conducts operations primarily through its antimicrobial technology platform and related commercialization initiatives. The company’s core business has historically revolved around its proprietary silver dihydrogen citrate chemistry, marketed for use in food processing environments, surface sanitation, and agricultural applications. Revenue generation has included direct product sales, licensing agreements, and strategic commercialization partnerships associated with its patented technologies and formulations.

Operations have largely been concentrated in the United States, though the company has pursued broader commercial and licensing opportunities in international markets where food safety and antimicrobial compliance standards support demand for sanitation technologies. PURE Bioscience’s principal assets include intellectual property portfolios, patents related to antimicrobial formulations, and regulatory approvals associated with silver-based disinfectant technologies. Public disclosures have referenced relationships with distributors and commercial partners supporting market access and product deployment, though publicly available information regarding large-scale joint ventures or major international subsidiaries remains limited.

Strategic Position & Investments

PURE Bioscience has historically positioned itself around increasing demand for enhanced food safety standards, pathogen control, and non-antibiotic antimicrobial technologies. Strategic initiatives have included expanding commercial adoption of its silver dihydrogen citrate products, pursuing regulatory clearances, and developing applications across food processing, agriculture, and institutional sanitation sectors. The company’s strategy has also emphasized intellectual property protection and licensing opportunities tied to proprietary antimicrobial formulations.

Public filings and corporate disclosures indicate that PURE Bioscience has invested in product development, regulatory compliance, and commercialization infrastructure associated with its antimicrobial platform. The company has also explored opportunities tied to emerging sanitation and infection-control markets, particularly in areas where pathogen mitigation and food safety compliance remain operational priorities. Data regarding significant acquisitions or large-scale portfolio investments is limited in publicly available sources, and some historical strategic initiatives appear to have evolved over time in response to capital constraints and changing commercial priorities.

Geographic Footprint

PURE Bioscience is headquartered in California, United States, and its operational activities have primarily focused on the North American market. The company’s commercial efforts have targeted U.S.-based food processors, institutional users, and agricultural customers, particularly in sectors subject to stringent sanitation and food safety regulations. Its market presence has historically depended on distribution relationships and commercialization partnerships rather than extensive global manufacturing infrastructure.

The company has also pursued international opportunities through licensing and distribution arrangements in select foreign markets where antimicrobial technologies are used in food safety and sanitation applications. However, publicly available information indicates that PURE Bioscience maintains a relatively concentrated operational footprint compared with larger multinational chemical or life sciences companies. Data regarding material international operational assets or extensive overseas subsidiaries is inconclusive based on available public sources.

Leadership & Governance

PURE Bioscience operates under a corporate governance structure led by executive management and a board of directors responsible for overseeing commercialization strategy, regulatory compliance, and capital allocation. The company’s leadership approach has historically emphasized leveraging proprietary intellectual property, expanding commercial partnerships, and positioning antimicrobial technologies within regulated food safety and sanitation markets.

Key executives and leadership figures publicly associated with the company include:

• Hank Lambert – Chief Executive Officer and Director
• David R. Hill – Chief Financial Officer
• Richard A. Brown – Chairman of the Board

The company’s leadership strategy has focused on advancing commercialization opportunities for its antimicrobial platform while maintaining regulatory compliance and intellectual property protections. Public filings, including SEC filings, indicate that management priorities have included operational efficiency, strategic partnerships, and long-term development of food safety and sanitation applications tied to the company’s core technology portfolio.